Clinical Trials on Wet Macular Degeneration

Total 54608 results

Opthea Limited

Completed

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Neovascular Age-related Macular Degeneration

United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Pfizer

Completed

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. (MACURELI)

Neovascular Age-related Macular Degeneration

Belgium
Dr Irmela MANTEL

Completed

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

Neovascular Age-related Macular Degeneration
Hospital Hietzing

Completed

Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor

Neovascular Age-related Macular Degeneration
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE)

Neovascular Age-related Macular Degeneration

Germany, Turkey, Austria, Canada, Czechia, United Kingdom, Hungary, Italy, Lithuania, Guatemala, France, Ireland, Argentina, Portugal, Spain, Sweden, Greece, Switzerland, Slovakia, Finland, Netherlands, Colombia, Mexico, Panama
Biocad

Withdrawn

Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration
Institut de la Macula y la Retina
Centro Medico Teknon

Completed

FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration (FUSION)

Exudative Age-related Macular Degeneration

Spain
Pfizer

Withdrawn

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

Neovascular Age-related Macular Degeneration
Mie University

Unknown

Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration

Exudative Age-related Macular Degeneration

Japan
Stanford University

Completed

Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

Exudative Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Hoffmann-La Roche

Withdrawn

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (Diagrid)

Neovascular Age-Related Macular Degeneration

Denmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
Novartis Pharmaceuticals

Terminated

Russian Registry of Patients With nAMD

Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Neovascular Age Related Macular Degeneration

United States
Bio-Thera Solutions

Active, not recruiting

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration

China
Regeneron Pharmaceuticals
Bayer

Completed

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (CANDELA)

Neovascular (Wet) Age-Related Macular Degeneration

United States, Puerto Rico
Alcon Research

Completed

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE)

Exudative Age-Related Macular Degeneration

United States
Skyline Therapeutics

Recruiting

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Neovascular (Wet) Age-related Macular Degeneration

China, United States
4D Molecular Therapeutics

Recruiting

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Neovascular (Wet) Age-Related Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Neovascular (Wet) Age-related Macular Degeneration

United States
Northern California Retina Vitreous Associates
Genentech, Inc.

Completed

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. (RESCUE)

Recalcitrant Wet Age-related Macular Degeneration

United States
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
Centre Hospitalier Intercommunal Creteil

Completed

OCTA (Optical Coherence Angiography Tomography) Versus Structural OCT(Optical Coherence Tomography) in Neovascular AMD (Age Macular Degeneration) (QUAOBARE)

Macular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye Right

France
Medical University of Vienna

Completed

Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration
Johannes Gutenberg University Mainz
Novartis

Completed

Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (CAPTAIN)

Neovascular Age-related Macular Degeneration

Germany
Chengdu Kanghong Biotech Co., Ltd.
Beijing DMS Pharma Ltd.; The Digital Angiography Reading Center (DARC)

Completed

A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD (AURORA)

Neovascular Age-related Macular Degeneration

China
HuidaGene Therapeutics Co., Ltd.
Eye & ENT Hospital of Fudan University; Tianjin Medical University Eye Hospital

Recruiting

CRISPR/cas13-medIated RNA tarGeting tHerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Neovascular Age-related Macular Degeneration(nAMD)

China
Oregon Health and Science University

Recruiting

OCT Angiography in Wet AMD

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United States
REGENXBIO Inc.

Completed

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Exegenesis Bio

Recruiting

A Study of EXG102-031 in Patients With wAMD (Everest)

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

United States
King's College Hospital NHS Trust
King's College London

Active, not recruiting

Stereotactic Radiotherapy for Wet AMD (STAR) (STAR)

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United Kingdom
Kyowa Kirin Co., Ltd.

Terminated

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

Healthy Volunteers | Wet Age-related Macular Degeneration

Japan
Amgen
Parexel

Completed

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Spain, United States, Czechia, Serbia, Israel, Canada, Germany, Japan, Hungary, Poland, Korea, Republic of, Estonia, Hong Kong, Italy, Latvia, Lithuania, Mexico, Slovakia
Regeneron Pharmaceuticals

Completed

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Neovascular Wet Age-related Macular Degeneration (AMD)

United States
Innostellar Biotherapeutics Co.,Ltd

Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration

China
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
First Affiliated Hospital of Chongqing Medical...

Enrolling by invitation

Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD (IIT-A)

Exudative Age-Related Macular Degeneration

China
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Huabo Biopharm Co., Ltd.

Completed

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Duke University
Bausch & Lomb Incorporated

Completed

Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD

Neovascular Age-Related Macular Degeneration

United States
Subhransu K. Ray, M.D., Ph.D.
Bay Area Retina Associates

Completed

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (Lucedex)

Exudative Age-Related Macular Degeneration

United States
Sheba Medical Center
Universitaire Ziekenhuizen KU Leuven

Unknown

The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) (AMD)

Neovascular Age Related Macular Degeneration

Belgium, Israel
Bayer
Regeneron Pharmaceuticals

Completed

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. (PEGASUS)

Wet Macular Degeneration

Canada

3

Subscribe